Mode
Text Size
Log in / Sign up
N/A N=333,664

Anticoagulant Utilization Pattern

Atrial Fibrillation

Enrolled (actual)
333,664
Serious AEs
Results posted
Jun 2019
Primary outcome: Primary: Description of the Characteristics of Anticoagulant Initiators — 3.41; 4.30; 3.59; 3.82 Scores on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boehringer Ingelheim
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Description of the Characteristics of Anticoagulant Initiators
3.41; 4.30; 3.59; 3.82; 2.92; 3.62
PRIMARY
Percentage of Patients Initiating Specific Anticoagulant
15.7; NA; NA; NA; 5.4; 2.1
PRIMARY
Percentage of Patients Initiating Specific Anticoagulant Dose - Dabigatran
90.7; 90.7; 9.3; 9.3
PRIMARY
Percentage of Patients Initiating Specific Anticoagulant Dose - Apixaban
82.4; 84.4; 17.6; 15.6
PRIMARY
Percentage of Patients Initiating Specific Anticoagulant Dose - Rivaroxaban
74.0; 76.4; 18.4; 16.7; 7.6; 7.0
SECONDARY
Treatment Persistence Over Time
52.19; 52.86; 53.17; 51.58; 51.84; 48.29

Summary

This study plans to describe utilization patterns for oral anticoagulants over time in patients with non-valvular atrial fibrillation at risk for stroke using electronic claims data from a United States commercial insurance database.

Eligibility Criteria

Inclusion criteria

  • A recorded diagnosis of atrial fibrillation
  • Initiation of oral anticoagulant medication
  • Congestive Heart Failure, Hypertension, Age > 75, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack, Vascular Disease, Age 65-74, Sex Category (CHA2DS2-VASc) Score >=1
  • At least 18 years of age on the date of anticoagulant initiation

Exclusion criteria

  • Patients with missing or ambiguous age or sex information
  • Patients with documented evidence of valvular disease
  • Patients with less than 12 months enrolment in the UnitedHealth Research Database preceding the first dispensing
  • Patients with prior use of any oral anticoagulant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01847560). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search